25 November 2026

FY26 Annual General Meeting Chair's Address

Good afternoon, everyone,

It is my pleasure to welcome you to the 2026 Chrysos Corporation Annual General Meeting, the tenth since our formation. I'm Rob Adamson, Chair of Chrysos Corporation.

FY26 was our strongest year yet, and it marked the start of Chrysos' second decade. Ten years after our founding, PhotonAssay™ is increasingly regarded as standard practice rather than an emerging technology, delivering faster, safer, and more accurate analysis to the global mining industry.

Financially, we achieved record results:

- Revenue grew **33%** to **$88.1 million**
- EBITDA rose **68%** to **$27.2 million**, with EBITDA margin expanding from **24%** to **31%**
- We returned to post-tax profitability, with net profit after tax of **$1.8 million**

These results reflect the strength of our business model, the growing demand for PhotonAssay™, and the execution of our strategy.

Market Conditions and Business Model
An elevated gold price and a broad-based recovery in exploration activity drove record sample volumes through FY26. Our business model is built for these conditions. Each PhotonAssay™ unit is deployed under a long-term lease with a minimum monthly payment, providing a stable recurring revenue base through the cycle, while higher utilisation delivers meaningful upside when activity is strong.

I would also like to acknowledge the work of the Chrysos team in increasing the throughput capacity of our existing PhotonAssay™ units by up to 20%. These optimisation initiatives have unlocked meaningful additional processing capacity at minimal cost and highlight the substantial operating leverage within the business. Importantly, this work has only been implemented on part of the fleet to date, leaving further scope to increase capacity and returns as the improvements are rolled out more broadly.

In speaking with several major shareholders recently, I remarked that Chrysos had felt like a 1970s turbocharged car. We had our foot firmly on the accelerator, investing heavily in customer engagement and sales activity, signing a record 24 contracts during FY26 and a further 15 since year end, but there seemed to be considerable turbo lag before that effort translated into deployments. The update we provided last week demonstrates that this is now changing. The growing contract book is converting into deployed units, and I believe the turbo is finally starting to kick in.

This progress is a credit to the entire Chrysos team. Their persistence in the market, focus on customers and disciplined execution have built a strong pipeline of contracted business that is now being translated into deployed units, revenue and cash flow. Dirk will take you through how this is reflected in our revenue mix and financial performance.

Competitive Advantage
PhotonAssay™ is not just faster and safer—it is more accurate. Traditional fire assay methods often under-report gold in heterogeneous deposits or where free gold is present. Increasingly, customers are

discovering this, with several ASX and TSX announcements highlighting differences between fire assay and PhotonAssay™ results. This accuracy advantage is helping drive adoption and reinforcing our position as the industry's preferred solution.

Operational Highlights
We ended the year with 46 PhotonAssay™ units deployed across five continents, including our first in South America, and a contracted pipeline that has continued to grow. We remain the only provider partnered with all four of the world's major laboratory groups, and our direct relationships with leading miners continue to deepen.

Scale and Sustainability
As our installed base grows, operational leverage is driving stronger margins and cash generation. Together with the syndicated debt facility secured during the year, we are well placed to accelerate deployments.

Just as importantly, PhotonAssay™ continues to deliver compelling sustainability outcomes. An independent GHD assessment confirmed around 90% lower energy use, 76% lower CO_2 emissions and the complete elimination of hazardous lead waste compared with fire assay. To date, PhotonAssay™ has avoided more than 12,800 tonnes of CO_2 emissions and 6,200 tonnes of hazardous waste, while Chrysos recorded zero notifiable safety incidents during FY26.

Better economics, better safety and better environmental outcomes is a powerful combination, and one that continues to differentiate Chrysos globally.

Governance and Leadership
As Chrysos has grown, so has the complexity of running it, and we have continued to strengthen our governance to match. Elisha Civil, whose appointment in October 2025 I noted at last year's meeting, has now completed her first year on the Board, and her expertise in financial governance, risk management and capital markets has been valuable as we expand. Women now hold 33% of Board seats, ahead of the target we set in FY24. Today, Eric Ford and I retire by rotation and offer ourselves for re-election, as set out in the Notice of Meeting.

Looking Ahead
Our strategic direction is clear: accelerate our global roll-out, deepen customer partnerships, and maintain innovation and operational discipline.

With good momentum and a robust financial position, Chrysos is well placed for another year of growth in FY27 and beyond as we begin our second decade.

Finally, I want to thank our Managing Director and CEO, Dirk Treasure, our executive team, the entire Chrysos team, my fellow Directors, and our partners and customers. And to our shareholders—thank you for your continued support. We are proud of what we've achieved and excited about what lies ahead.

I will now invite Dirk to take you through our operational performance and FY27 outlook.

ENDS

About Chrysos Corporation
Headquartered in Adelaide, with operations expanding across the world, Chrysos Corporation combines science and software to create technology solutions for the global mining industry. The Company's flagship product PhotonAssay™ delivers faster, safer, more accurate and environmentally-friendly analysis of gold, silver, copper and other elements. For more information about Chrysos or its PhotonAssay™ technology, visit www.chrysoscorp.com

For media and investor enquiries, please contact:

Paul Ryan	Sodali & Co.	+61 409 296 511	paul.ryan@sodali.com
Sandrine Captieux	Sodali & Co.	+61 439 071 979	sandrine.captieux@sodali.com

This announcement was authorised for release by the Chair of Chrysos Corporation Limited.